Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) from a buy rating to a strong-buy rating in a report published on Saturday.

FMS has been the topic of a number of other reports. Erste Group Bank downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 5th. Jefferies Financial Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “moderate sell” rating to a “strong sell” rating in a research report on Tuesday, February 24th. Morgan Stanley reiterated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, January 27th. The Goldman Sachs Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a report on Tuesday, January 20th. Finally, Truist Financial set a $28.00 target price on shares of Fresenius Medical Care AG & Co. KGaA in a report on Monday, January 5th. Five analysts have rated the stock with a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Reduce” and a consensus target price of $28.00.

Fresenius Medical Care AG & Co. KGaA Stock Performance

Shares of NYSE:FMS opened at $23.16 on Friday. The company has a market capitalization of $12.94 billion, a price-to-earnings ratio of 12.13, a P/E/G ratio of 2.21 and a beta of 0.89. The firm’s 50 day simple moving average is $23.12 and its 200 day simple moving average is $23.81. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.26 and a quick ratio of 0.92. Fresenius Medical Care AG & Co. KGaA has a fifty-two week low of $20.94 and a fifty-two week high of $30.46.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last announced its quarterly earnings results on Saturday, February 14th. The company reported $1.69 earnings per share for the quarter. The business had revenue of $5.95 billion for the quarter. Fresenius Medical Care AG & Co. KGaA had a net margin of 5.03% and a return on equity of 8.73%. As a group, sell-side analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 2.49 earnings per share for the current year.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

Several hedge funds have recently bought and sold shares of FMS. Morgan Stanley raised its holdings in Fresenius Medical Care AG & Co. KGaA by 47.2% during the 4th quarter. Morgan Stanley now owns 2,939,839 shares of the company’s stock worth $70,027,000 after buying an additional 942,497 shares during the period. Bank of America Corp DE raised its holdings in Fresenius Medical Care AG & Co. KGaA by 279.7% during the 2nd quarter. Bank of America Corp DE now owns 337,316 shares of the company’s stock worth $9,637,000 after buying an additional 248,477 shares during the period. ABC Arbitrage SA raised its holdings in Fresenius Medical Care AG & Co. KGaA by 1,136.0% during the 4th quarter. ABC Arbitrage SA now owns 249,800 shares of the company’s stock worth $5,950,000 after buying an additional 229,589 shares during the period. Integral Health Asset Management LLC raised its holdings in Fresenius Medical Care AG & Co. KGaA by 44.4% during the 4th quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company’s stock worth $15,483,000 after buying an additional 200,000 shares during the period. Finally, Pzena Investment Management LLC raised its holdings in Fresenius Medical Care AG & Co. KGaA by 1.0% during the 3rd quarter. Pzena Investment Management LLC now owns 14,816,852 shares of the company’s stock worth $390,128,000 after buying an additional 153,870 shares during the period. 8.37% of the stock is currently owned by institutional investors and hedge funds.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.